ライフサイエンスコーパス: evidence-based treatment

1 ronic form of AN for which there is no known evidence-based treatment.

2 ed using the known natural history of ROP vs evidence-based treatment.

3 the need for randomized trials to allow for evidence-based treatment.

4 ethodological quality, and identification of evidence-based treatments.

5 impede rural veterans from engaging in these evidence-based treatments.

6 to improve quality by quantifying the use of evidence-based treatments.

7 ldren and adolescents for which there are no evidence-based treatments.

8 fit from further research and development of evidence-based treatments.

9 Childhood mood disorders lack sufficient evidence-based treatments.

10 o be offered in primary care alongside other evidenced based treatments.

11 med with each compound is used to propose an evidence-based treatment algorithm.

12 Clear, focused, and evidence-based treatment algorithms are needed to suppor

13 s like ARIA and EPOS provide clinicians with evidence-based treatment algorithms for allergic rhiniti

14 lt PAH have been used to treat children, but evidence-based treatment algorithms for children are lac

15 The underuse of evidence-based treatments and delayed reperfusion among

16 ogy inpatient service more commonly received evidence-based treatments and had a lower risk of mortal

17 Clinical trials to support evidence-based treatments and the development of disease

18 ology, outcomes, causes and pathophysiology, evidence-based treatment, and a call for action.

19 tention of drug users in centres offering no evidence-based treatment, and imprisonment for possessio

20 siology of smoke inhalation injury, the best evidence-based treatments, and challenges and future dir

21 al in-person engagement session, delivery of evidence-based treatments, and regular follow-up by mast

22 aphasia after stroke, providing an effective evidence-based treatment approach in this population.

23 Prompt recognition and an evidence-based treatment approach is the key to successf

24 population and the lack of standardized and evidence-based treatment approaches make treatment a dif

25 Evidence-based treatments are available for patients wit

26 Evidence-based treatments are available for the manageme

27 No evidence-based treatments are available to reduce this r

28 iscrepancy, Martin Raw, Honorary Lecturer in evidence-based treatment at Guys, Kings and St Thomas' S

29 ally need to focus on improving the rates of evidence-based treatment at sites with high proportions

30 nts and for development and testing of novel evidence-based treatments, both trauma-focused and non-t

31 There is no evidence-based treatment, but various systemic immunomod

32 croorganisms has the potential to facilitate evidence-based treatment decisions, antimicrobial select

33 allenges with scaling up multiple structured evidence-based treatments (EBTs), a transdiagnostic trea

34 Evidence-based treatment established for these condition

35 ogy and manage both vascularized PEDs, where evidence-based treatment exists, and nonvascularized PED

36 This is the first evidence-based treatment for a skeletal muscle channelop

37 iews of extending behavioural activation, an evidence-based treatment for depression, to the negative

38 However, there is still no firmly evidence-based treatment for heart failure with preserve

39 cognitive behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been teste

40 Although urban-rural disparities in evidence-based treatment for myocardial infarction in Ch

41 Mexiletine is the first evidence-based treatment for nondystrophic myotonias.

42 Cognitive processing therapy (CPT), an evidence-based treatment for posttraumatic stress disord

43 Bright light therapy is an evidence-based treatment for seasonal depression, but th

44 eneficial effects are additional to those of evidence-based treatments for acute myocardial infarctio

45 ably more deaths per year than would various evidence-based treatments for cardiovascular disease.

46 the breadth of target problems that current evidence-based treatments for child posttraumatic stress

47 tus and physicians' adherence with providing evidence-based treatments for coronary artery disease (C

48 Significant underuse of evidence-based treatments for depression persists in pri

49 arate and modular/integrated arrangements of evidence-based treatments for depression, anxiety, and c

50 zed controlled trials have produced separate evidence-based treatments for depression, anxiety, and c

51 sease risk, and the increased application of evidence-based treatments for established coronary heart

52 There is a conspicuous paucity of evidence-based treatments for FNS.

53 Evidence-based treatments for major depressive disorder

54 Evidence-based treatments for metastatic, human epiderma

55 The promise of evidence-based treatments for morphea in the near future

56 , no randomized clinical trials have studied evidence-based treatments for OVC in low-resource settin

57 veterans who have poor adherence to existing evidence-based treatments for posttraumatic stress disor

58 Evidence-based treatments for posttraumatic stress disor

59 This article offers (a) an overview of evidence-based treatments for PTSD, (b) a description of

60 th chronic kidney disease, but there are few evidence-based treatments for reducing cardiovascular ev

61 r depression by age 18 years yet few receive evidence-based treatments for their depression.

62 Promote the further development of evidence-based treatments for tobacco cessation, includi

63 Integrating evidenced-based treatment for depression with evidenced-

64 is a need for comparative studies to provide evidence-based treatment guidance for biologic agents in

65 Evidence-based treatment guidelines are not available fo

66 RATIONALE: The development of evidence-based treatment guidelines for pediatric pulmon

67 Adherence to evidence-based treatment guidelines has been proposed as

68 Adherence to evidence-based treatment guidelines in rectal cancer is

69 inical judgment in situations not covered by evidence-based treatment guidelines.

70 , and current treatment practices lag behind evidence-based treatment guidelines.

71 n emphasis on meta-analyses and contemporary evidence-based treatment guidelines.

72 Evidence-based treatment has led to dramatic improvement

73 New evidence-based treatments have greatly expanded the medi

74 a promising way to build on the strengths of evidence-based treatments, improving their utility and e

75 expectancy of a patient strongly influences evidence-based treatment in acute myocardial infarction.

76 , partly because of high levels of empirical-evidence-based treatment in smear-negative patients.

77 ant psychosocial problems, for which we have evidence-based treatments, many patients still do not re

78 M structured its review according to current evidence-based treatment modalities in HCC and prioritiz

79 Clinical considerations for evidence-based treatment of borderline personality disor

80 ve been achieved, however identification and evidence-based treatment of intellectual disabled offend

81 Moreover, the integration of evidence-based treatments of adolescent substance abuse

82 pproach outperformed usual care and standard evidence-based treatments on multiple clinical outcome m

83 as Leigh syndrome and there are very limited evidence-based treatment options available.

84 testicular cancer, and scientifically driven evidence-based treatment options should improve quality

85 disease is challenging because there are few evidence-based treatment options, and pulmonary vasodila

86 were less likely than whites to receive many evidence-based treatments, particularly those that are c

87 es has the potential to enable comprehensive evidence-based treatment plans to be implemented quickly

88 acilitate the development of child-specific, evidence-based treatment plans.

89 There is no evidence-based treatment recommendation for individuals

90 As a result, evidence-based treatment recommendations are possible fo

91 Clinical trials have led to evidence-based treatment recommendations for advanced te

92 We provide evidence-based treatment recommendations using the GRADE

93 When compared to evidence-based treatment recommendations, these changes

94 sistent and reflect the need for efficacious evidence-based treatment regimens.

95 Evidence-based treatments should be available to these i

96 T, underscoring the continued unmet need for evidence-based treatment strategies in HFpEF.

97 release, and sooner, than those treated with evidence-based treatments such as methadone, suggesting

98 release, and sooner, than those treated with evidence-based treatments such as methadone, suggesting

99 disorder, clinicians should offer or arrange evidence-based treatment, such as medication-assisted tr

100 okers to attempt to quit and connect them to evidence-based treatment that includes pharmacotherapy a

101 Evidence-based treatments that achieve optimal energy in

102 multicenter registries are needed to provide evidence-based treatments to improve in-hospital outcome

103 Evidence-based treatment trials for adolescents with ano

104 Evidenced-based treatment trials for adolescents with bu

105 settings, accessibility and acceptability of evidence-based treatments vary, and patients may seek a

106 In China, evidence-based treatments were provided less often in 20

107 cause the intervention facilitates access to evidence-based treatment, which typically is less availa